1 / 65

Treatment in Autism spectrum disorders

Treatment in Autism spectrum disorders. Dr K Razjouyan Associate Professor of Shahid Beheshty University and Medical Sciences. DSM IV TR Criteria. Autism spectrum disorders (ASDs) are a heterogeneous group of neurodevelopmental disorders Deficits in social communication

zaynah
Télécharger la présentation

Treatment in Autism spectrum disorders

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Treatment in Autism spectrum disorders Dr K Razjouyan Associate Professor of ShahidBeheshty University and Medical Sciences

  2. DSM IV TR Criteria • Autism spectrum disorders (ASDs) are a heterogeneous group of neurodevelopmental disorders • Deficits in social communication • Deficits in language • Repetitive behaviors and restricted interests

  3. DSM 5 • the three DSM-IV-TR domains become two in DSM-5 • Must meet criteria 1, 2, and 3: • 1. Clinically significant, persistent deficits in social communication and interactions • 2. Restricted, repetitive patterns of behavior, interests, and activities • 3. Symptoms must be present in early childhood (but may not become fully manifest until social demands exceed limited capacities)

  4. Facts about autism • In 2012, the CDC estimated the prevalence of ASD as 1 in 88 children • An estimated increase of 78% from 2002 to 2008 • A 2011–12 telephone survey by the center’s National Center for Health Statistics suggested that 1 in 50 U.S. school-aged children is now diagnosed with ASD

  5. Facts about ASD • As more children with ASD transition into adulthood, the need for comprehensive services for adults with autism will also increase

  6. Comorbidities • The individuals with autism, 35% had another comorbid psychiatric disorder • Comorbidities can substantially increases health care expenditures • They can impede progress in educational and therapeutic settings • Cause significant distress for patients and their families

  7. Treatment • The treatment is complex and different • There is no single, definitive treatment for ASD • Early intensive behavioral interventions can reduce core autistic symptoms and improve developmental outcomes • No pharmacotherapeutics have yet shown a consistent primary effect on the core social disability of autism • Appropriate pharmacotherapy can enhance an autistic person’s ability to benefit from educational and behavior modification techniques

  8. Treatment • In a database analysis of children with ASD aged 2–17 years, 27% of all participants took at least one psychotropic medication, with greatest rates of use (66%) in adolescents. • 80% of children diagnosed with a comorbid psychiatric disorder were taking at least one psychotropic medication

  9. Treatment • For most medications, limited data are available • Currently, only two medications—Risperidone and Aripiprazole—have U.S. Food and Drug Administration (FDA) indication for use in autism

  10. Common targets of medication • Anxiety • ADHD symptoms • Compulsions and interfering repetitive behaviors • Sleep disturbance • Irritability • In higher-functioning ASD, depression is also common

  11. Stimulants • Co-diagnosis is allowed in DSM-5 • Response rates tend to be lower • Symptom improvement is often less robust • Side effects are more frequently reported • Significantly more children are unable to tolerate commonly prescribed medications

  12. Stimulants • A large double-blind, placebo-controlled, crossover trial conducted by (RUPP) autism network • The effects of methylphenidate 0.125–0.5 mg/kg/day were investigated in 72 children with ASD over one-week periods • Improvement in the ABC-hyperactivity subscale score was reported, with a small to medium effect size • 49% percent of children were determined to be responders by a combined measure of improvement in hyperactivity and global severity, as determined by (CGI-I)

  13. Stimulants • The response rate was lower than the 70%–80% response observed in the Multisite Multimodal Treatment of Children with ADHD study, and side effects were more common • A small placebo controlled, crossover trial of 14 preschool-aged children with developmental delay or PDD reported a similar response rate and side-effect profile

  14. Stimulants • Adverse effects, which were more common with the higher dose, included social withdrawal and irritability • Irritability is a particular vulnerability with psychostimulant use in ASD • Given the rapid onset of effect and side effects, short trials might be used to readily clarify potential treatment response

  15. Atomoxetine (Strattera) • A retrospective study noted a 60% response rate as determined by a rating of “much improved” or “very much improved” on the CGI-I • Specific improvements were noted in conduct, hyperactivity, inattention, and learning • One large placebo-controlled trial of atomoxetine (dosed at 1.2 mg/kg/day) in 97 children with ASD found improved ADHD symptoms • Nausea, decreased appetite, and mid-cycle awakenings

  16. Alpha-2-adrenergic receptor agonists: Clonidine • An open-label trial with clonidine in 19 children with ASD • Noted improved sleep and, to a lesser extent, ADHD symptoms, aggression, and mood instability • Two small placebo-controlled studies reported positive findings, with improved irritability, hyperactivity, inappropriate speech, oppositionality, stereotypy, sensory reactivity, and global illness severity • In the smaller sample study, however, no benefit for clonidine over placebo was identified based on clinician ratings

  17. Alpha-2-adrenergic receptor agonists: Guanfacine • A chart review of 80 youth with ASD treated with guanfacine demonstrated effectiveness in 24% of participants, with specific improvements in hyperactivity, inattention, insomnia, and tics • Asperger’s disorder or PDD not otherwise specified and those without mental retardation showed a higher response rate

  18. Guanfacine • A small placebo-controlled, crossover study of 11 children with developmental disorders (the majority of whom had ASD diagnoses) demonstrated improved hyperactivity • 48% determined to be responders by a 50% reduction in hyperactivity symptoms • Drowsiness and irritability, Daytime sedation and mid-cycle awakenings

  19. Atypical antipsychotics • Attenuate the maladaptive symptoms of patients with PDDs, and potentially target core socialization deficits

  20. Risperidone • In 2002, the RUPP Autism Network published results of a multisite, controlled trial of Risperidone in ASD (n = 101; age range, 5–17 years) • An eight-week active treatment phase followed by a four month open-label continuation phase and two-month discontinuation phase • 69% of the participants in the Risperidone group met responder status • Two-thirds of participants maintained this benefit at six months in the open-label phase

  21. Risperidone • Improvement has also been observed in secondary measures of restrictive, repetitive, and stereotyped behaviors; adaptive functioning; hyperactivity; social withdrawal; and communication

  22. The most common adverse events with Risperidone • Somnolence • Increase in appetite • Fatigue • Upper respiratory tract infection • Increase in saliva • Constipation • Dry mouth • Tremor

  23. The most common adverse events with risperidone • Muscle stiffness • Dizziness • Involuntary movements • Repetitive behavior • Rapid heartbeat • Confusion • Increase in weight • Possible hyperprolactinemia, which could result gynecomastia or galactorrhea

  24. Risperidone • Risperidone received FDA approval on October 10, 2006 for the treatment of irritability associated with autistic disorder • Including symptoms of aggression, deliberate self-injury, temper tantrums, and quickly changing moods in children and adolescents aged five to 16 years

  25. Aripiprazole (Abilify) • In 2009, Aripiprazole became the second agent approved by the FDA for managing irritability in children 6–17 years old with autism • A decision based on positive results from two multisite, industry-sponsored, randomized, double blind, placebo-controlled trials for the treatment of irritability associated with autistic disorder • Including symptoms of aggression towards others, deliberate self-injurious behavior, temper tantrums, and quickly changing moods

  26. Abilizole • In both studies, sedation and somnolence were the most commonly reported adverse effects • Aripiprazole was associated with significantly more weight gain at eight weeks compared to placebo • Treatment-emergent EPS occurred at rates of 14.9%–23% in treatment groups compared to 8%–11.8% in placebo groups. • Vomiting was twice as common with active treatment (13.7%)

  27. Abilizole • HDL levels declined in 30% of individuals • Clinically significant elevations of total cholesterol, low-density lipoproteins, triglycerides ,and serum glucose were less common • No abnormal ECG finding

  28. Olanzapine • Two small open-label trials of olanzapine reported high response rates though results from an additional two studies were less robust • Weight gain was substantial across studies and greater than observed with Risperidone and Aripiprazole • Mild, transient sedation was also common in all studies

  29. Quetiapine • Open-label studies of Quetiapine have generally found minimal efficacy and poor tolerability due to excessive sedation, weight gain, and increased aggression or agitation • One study suggested Quetiapine may be helpful for sleep disturbance and aggression

  30. Ziprasidone • In one open-label study, one case series, and two case reports Ziprasidone has shown promise in the treatment of irritability, aggression, hyperactivity, and impulsivity in autism • Initial sedation was common and in two patients with comorbid bipolar disorder, symptoms were rated as “much worse” with Ziprasidone

  31. Paliperidone • The extended-release active metabolite of Risperidone, in patients with ASD is limited to one open-label study and three case reports • Results from a study of 25adolescents with autism and severe irritability are encouraging, with 84% of participants showing significant improvement in irritability • Weight gain and increased serum prolactin were common, and mild to moderate EPS were reported in 4 individuals

  32. Clozapine • Small case reports • Clozapine is not considered a first line agent for severe irritability, given its potentially serious side effects of agranulocytosis, seizures, and cardiomyopathy • The need for frequent blood draws

  33. Atypical antipsychotics • Atypical antipsychotics should probably be reserved for children with comorbid irritability, aggression, and/or self-injurious behavior • Whose hyperactivity and impulsivity are severe and/or extremely dangerous • Fatigue, sedation, dizziness, drooling, and EPS can occur with all antipsychotics

  34. Atypical antipsychotics • Tardive dyskinesia can potentially occur with atypical antipsychotics, and monitoring for abnormal movements should be performed periodically • Neuroleptic malignant syndrome is a rare but potentially serious side effect that can occur with typical and atypical antipsychotics • it is recommendedto monitor baseline and subsequent measures, including, but not limited to, the following: height, weight, BMI

  35. Haloperidol • Haloperidol (doses 1–2 mg/day) to be efficacious in young children (ages 2–8 years) • For treatment of stereotypies, aggression, withdrawal, hyperactivity, and irritability • A positive treatment effect on learning • Older children responded better than younger children.

  36. Haloperidol • Sedation and acute dystonic reactions were the most frequent short-term adverse effects • Dyskinesias were also frequent occurring especially upon medication withdrawal • Its use is reserved for severe treatment-refractory symptoms associated with autism.

  37. SEROTONERGIC AGENTS For compulsive and repetitive behavior Anxiety depression

  38. Clomipramine • In open trials and case reports: Positive reports noted improvements in repetitive behaviors, aggression, social engagement, language, adventitious movements, and adaptive behavior • In the largest of the open studies (n = 35 adults), 13 participants experienced adverse effects, with 3 reporting seizures • Two of the open-label trials in children reported difficulties with agitation and aggression

  39. Clomipiramine • In two blinded controlled trials , each with 12 participants, reported improvement in overall autistic symptoms and also in compulsive behaviors and anger as compared to both placebo and Desipramine • One participant had a prolonged QTC interval (0.45 seconds), and another became tachycardic (resting heart rate 160–170 beats per minute) • These effects resolved after dose reduction

  40. SSRIs • Open trials in children and adults with ASD have been mostly positive • Notable improvements in obsessive-compulsive symptoms, anxiety, depressive symptoms, aggression, and overall symptom severity • Difficulty with activation side effects and agitation were frequent in some reports. • Placebo-controlled trials of SSRIs in children have been mostly discouraging

  41. Fluvoxamine • A 12-week double blind investigation of fluvoxamine in 30 adults with ASD noted improvement in repetitive thoughts and behaviors, aggression, language function, and maladaptive behavior • Side effects mostly limited to nausea and sedation

  42. Fluoxetine • A double-blind, placebo-controlled study has been conducted for fluoxetine in children with ASD in 2005 • Low-dose liquid fluoxetine was superior to placebo in the treatment of repetitive behaviors, and it was only slightly, and not significantly, superior to placebo on global improvement score • Several other studies of fluoxetine have demonstrated efficacy in treating ASD symptoms • Case reports have documented decreases in symptoms such as outbursts , rituals/OCD behaviors , depressive symptoms , and trichotillomania

  43. Citalopram • Results from a 12-week National Institute of Mental Health–funded, multicenter, placebo-controlled study of citalopram (mean dose, 16.5 mg daily) in 149 children with ASD found no difference in repetitive behaviors or global improvement compared to placebo • Activation side effects ,impulsivity, hyperactivity, distractibility, stereotypy, and insomnia were common • 2 children had seizure episodes

  44. SSRIs • Despite the positive placebo-controlled trials with SSRI treatment in adults with ASD, findings in children have been mostly negative • Age-related differences in serotonin functioning • Because of the limited alternatives and sometimes severe repetitive and compulsive behaviors that often impair functioning, a trial with an SSRI in children and adolescents might be considered

  45. Buspirone • Buspirone is a partial serotonin receptor type 1A agonist • Improved anxiety, irritability, and hyperactivity in ASD in a few case reports and one open-label study with 22 participants • Has a relatively mild side-effect profile in comparison to SSRIs and neuroleptics • It could be an option in who have tolerated SSRIs poorly

  46. Mirtazapine • A serotonin reuptake inhibitor at low doses with Noradrenergic effects (a2 antagonism) at higher doses • An open-label study of mirtazapine reported significant overall improvement in 34.6% but no improvement in core autistic features • Show some promise in sexual behaviors in ASD • It could be an option in who have tolerated SSRIs poorly esp. in anxiety and sleep disorder

  47. Venlafaxine • Carminati and colleagues (2006) published three case reports on the use of low-dose venlafaxine (18.75 mg daily) in adolescents and young adults with ASD. • Venlafaxine was prescribed to improve self-injurious behavior and attention deficit/hyperactivity disorder (ADHD)-like symptoms in ASD. • Hollander and colleagues (2000) conducted a retrospective clinical study of venlafaxine :Six of ten were rated as responders, with improvement noted in repetitive behaviors, restricted interests, social deficits, communication, inattention, and hyperactivity • Sideeffects included activation, nausea, and polyuria.

  48. Drugs affecting glutamate function

  49. Lamotrigine • The drug attenuates some forms of cortical glutamate release • Lamotrigine and placebo showed no difference in effect as measured by the ABC, Vineland scales, Childhood Autism Rating Scale (CARS), and PreLinguistic Autism Diagnostic Observation Scale. • Most common side effects: Insomnia ,hyperactivity, rash

  50. Amantadine • A noncompetitive NMDA antagonis • No significant difference was found between drug and placebo on parent ratings, although clinician-rated measures of hyperactivity and inappropriate speech showed statistically significant improvement. • The authors reported that the medication was well tolerated

More Related